What's in Andrea Roe, MD, MPH's pipeline?

Andrea Roe, MD, MPH has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Andrea Roe, MD, MPH's portfolio?

Top competitors by shared drug class: Organon and Co, University of Pittsburgh.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/andrea-roe-md-mph.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Andrea Roe, MD, MPH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Andrea Roe, MD, MPH pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Etonogestrel/ethinyl estradiol vaginal ring	Etonogestrel/ethinyl estradiol vaginal ring	marketed	Combined hormonal contraceptive	Progesterone receptor, estrogen receptor	Contraception / Reproductive Health

Therapeutic area mix

Contraception / Reproductive Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Organon and Co · 1 shared drug class
University of Pittsburgh · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Andrea Roe, MD, MPH:

Cite this brief

Drug Landscape (2026). Andrea Roe, MD, MPH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/andrea-roe-md-mph. Accessed 2026-05-17.